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Summary:   18 
This is the first report to document transplacental transmission of Anaplasma 19 
phagocytophillum in the horse. A 4-year old late term pregnant mare presented for a recent 20 
onset of pyrexia due to equine granulocytic anaplasmosis (EGA). She was hospitalized for 21 
treatment with oxytetracycline and monitoring of high-risk foaling due to significant 22 
thrombocytopenia. Parturition occurred overnight and the foal was PCR positive for A. 23 
phagocytophilum at birth. The foal was slow to stand and nurse, with signs of neonatal 24 
encephalopathy and anaplasmosis (thrombocytopenia).  Therapy with oxytetracycline resulted 25 
in complete clinical recovery of the mare and foal within 5 days. Congenital anaplasmosis 26 
should be considered in any foal delivered to a mare suffering from EGA during late term 27 
pregnancy and guide appropriate antimicrobial therapy. 28 
 29 
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 31 
Abbreviations:  32 
BPM, beats per minute; EGA, Equine granulocytic anaplasmosis; IV, intravenous; PCR, 33 
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Case History 36 
A 4-year-old 670 kg Oldenburg maiden mare presented on day 341 of gestation with a two-day 37 
history of decreased appetite, and a fever of 40 °C which developed that morning. She was 38 
bred using frozen semen via artificial insemination, with normal reproductive ultrasonography 39 
on days 15, 30 and 60 of gestation. The mare was routinely vaccinated for equine herpes virus 40 
(Pneumabort-K+1b1) during gestation. She lived with one other unaffected horse in an area 41 
known to be endemic for A. phagocytophilum and with a high tick population. The mare was 42 
fed free choice Timothy hay, 4.5 kg Timothy/alfalfa cubes, and 2.7 kg grain per day. Flunixin 43 
meglumine was administered intravenously (1.1 mg/kg IV) the morning of admission. 44 
Clinical Findings 45 
At presentation, the mare showed a normal rectal temperature (38.1 °C), mild tachycardia (48 46 
beats per min (BPM)), and tachypnea (42 breaths per min). No nasal discharge was present, 47 
auscultation of the upper airway and thorax was unremarkable, and the tachypnoea resolved 48 
once the mare adjusted to the hospital environment. Abdominal ultrasonography was 49 
unremarkable for a late term pregnant mare, with normal foetal fluid depth and echogenicity, 50 
normal foetal activity, and an average foetal heart rate of 96 BPM. 51 
Initial bloodwork indicated normovolaemia (packed cell volume (PCV) 40% (reference range 52 
(rr): 32-53%), total solids 70 g/L (rr: 52-79 g/L), lactate 0.6 mmol/L (rr: <2 mmol/L)). 53 
Complete haematology showed a slight leukopenia at 4.12 109/L (rr: 5.9-11.2 109/L) and mild 54 
neutropenia of 2.0 109/L (rr: 2.3-9.1 109/L) with morulae of the intracellular bacterium A. 55 
phagocytophilum being observed within neutrophils (Figure 1). Significant thrombocytopenia 56 
was present at 19 109/L platelets (rr: 92-253 109/L). Biochemistry was unremarkable, aside 57 
from a hyperfibrinogenemia of 5.0 g/L (rr: 1.0-4.0 g/L) and an elevated indirect bilirubin of 58 
145 µmol/L (rr: 3-51 µmol/L). An intravenous catheter (14g 13cm IV polyurethane catheter-59 
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over-needle2) was placed in the left jugular vein. The mare was sedated with 0.15 mg/kg 60 
xylazine (AnaSed LA)3 IV and, following local anaesthetic administration (2% lidocaine)4, a 61 
Foalert system5 was sutured in place according to manufacturer’s instructions. Therapy with 62 
7.5 mg/kg IV oxytetracycline (Oxytet 100)6 every 12 hours was initiated and adjusted to 10 63 
mg/kg IV twice daily post-partum, with the mare treated for five days in total. The mare was 64 
fed according to her usual diet and monitored closely for signs of foaling. 65 
The mare became restless at 12am the evening after presentation and a filly was naturally 66 
delivered at 3.30 am, following 15 minutes of Stage II labour. The foal was in anterior 67 
longitudinal and dorsosacral position with one forelimb flexed at the elbow. Spontaneous 68 
breathing was observed immediately following birth with the heart rate increasing to 120 BPM. 69 
Post-partum physical examination was unremarkable for a 52 kg full-term foal, with a grade 2 70 
systolic murmur identified over the heart base. The umbilicus was dipped in 0.5% 71 
chlorohexidine gluconate (1:4 dilution of 2% Chlorohexidine)3 and the mare and foal were 72 
allowed to bond under close observation. 73 
Following parturition the mare became extremely protective and required sedation (0.3 mg/kg 74 
xylazine IV once; 0.02 mg/kg acepromazine IV twice (Aceproject)7 to permit veterinary care 75 
of her foal. Flunixin (1 mg/kg IV; Flunixiject)8 was also administered to supply analgesia. The 76 
mare’s placenta was retained for 7 hours post foaling, despite repeated administration of 77 
oxytocin (7 units intramuscularly; Oxytocin)8, hand-walking and gradual traction by a water-78 
filled glove attached to the exterior portion of the placenta. Following expulsion of the main 79 
body of the placenta, the tip of the non-gravid horn remained retained. Uterine lavage was 80 
performed following standard protocols (15L of 0.9% sodium chloride9) and the residual 81 
placenta was weighted to provide continuous gentle traction. Intravenous crystalloid fluid 82 
therapy (30 ml/kg bolus Plasma-lyte A)10 was also initiated, as the mare remained agitated 83 
following foaling with no water intake. Additionally, she was treated with Domperidone (6cc 84 
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Equidone Gel by mouth q24h)11 due to limited milk production. Based on the mare’s 85 
thrombocytopenia, retained placenta, and risk of haemorrhage, coagulation testing and blood 86 
cross matching were performed pre-emptively, demonstrating a normal prothrombin time (12.2 87 
s; rr: 10.9-14.5 s) and a fast partial thromboplastin time (40.9 s; rr: 54.7-69.9s). Repeat 88 
haematology confirmed ongoing thrombocytopenia (15 109/L), but resolution of neutropenia 89 
(4.0 109/L) with A. phagocytophilum still observed. Administration of oxytocin (7-10 units 90 
intramuscularly q4-6h) was continued and treatment with enrofloxacin (7.5 mg/kg IV q24h; 91 
Baytril 100)12 and polymyxin B13 (2500 units/kg IV q12h for 2 doses) were added to counteract 92 
infection and endotoxaemia, respectively. The application of traction (by a water-filled glove 93 
connected via umbilical tape) on the retained placental tip resulted in its successful and 94 
complete expulsion at 8 hours post-partum. Histopathology of examined sections of placenta 95 
was unremarkable, with no evidence on inflammation. Uterine lavage was repeated 3 times 96 
over the next 2 days, followed by infusion of 6g ampicillin14. Enrofloxacin and oxytocin 97 
therapy were discontinued after resolution of all clinical abnormalities on day 3. 98 
The filly failed to stand within 1 hour following delivery, despite a normal gestational length 99 
and parturition. Initial bloodwork showed an elevated PCV, marked hyperlactataemia, 100 
hypoglycaemia, and hypercreatininemia (Table 1). No morulae were identified on a blood 101 
smear. An intravenous catheter (14 Ga 15cm polyurethane over-the-wire catheter)2 was, 102 
therefore, placed in the left cephalic vein, and 40 ml/kg Plasma-lyte A with 2.5% dextrose 103 
(Dextrose 50%)15 was administered IV over the following hour. Blood was obtained for culture 104 
and anaplasma polymerase chain reaction (PCR), prior to any intake of colostrum. Anaplasma 105 
phagocytophilum (MSP2 gene) qPCR (Real-time PCR Research and Diagnostic Core Facility, 106 
University of California, Davis School of Veterinary Medicine, CA 95616, USA) was positive, 107 
whilst blood culture yielded no growth. 108 
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Four hours after delivery the filly’s vital parameters were normal (temperature 38.1 °C, heart 109 
rate 100 bpm, respiratory rate 40 breaths per min), but she remained unable to stand unaided. 110 
Complete haematology at this time was unremarkable aside from a mild thrombocytopenia of 111 
87 109/L, low globulin levels, increased indirect bilirubin and elevated creatine kinase (Table 112 
1). Serum creatinine concentrations had improved to 168 /µmolL and the initial serum amyloid 113 
A (SAA) was normal at 0 µg/mL (rr: <50 µg/mL). Pending blood culture and anaplasma PCR 114 
results, the foal was started on oxytetracycline (7.5 mg/kg IV q12h) and amikacin (20 mg/kg 115 
IV q24h; Amiglyde-V)16. Vitamin E and selenium was supplemented (1ml IM once; E-Se)17. 116 
The foal received 2L frozen hyperimmune plasma (HiGamm-Equi)18 within the first 24 hours 117 
of life, as the mare lacked colostrum production and frozen colostrum was unavailable. To 118 
facilitate nutritional support, the filly was initially fed via an indwelling nasogastric tube (12Fr 119 
108cm feeding tube with stylet)2. She was frequently assisted to rise and encouraged to nurse, 120 
successfully latching on and nursing at 10 hours of age. By 18 hours post-partum the foal was 121 
urinating normally, with a urine specific gravity of 1.005. However, her blood lactate remained 122 
elevated (3.2-4.2 mmol/L) despite normohydration (PCV 38-40 % and total solids 48-52 g/L) 123 
and fluid administration (170 ml/kg Plasma-lyte A over 24 hours), suggesting type B 124 
hyperlactataemia (Table 1). Adequate immunoglobulin levels were confirmed (IgG > 8.0 g/L) 125 
at 24 hours of age, but the SAA had increased to 145 µg/mL, suggesting an ongoing 126 
inflammatory or infectious process. Intravenous fluid therapy was discontinued by 36 hours of 127 
age, as the foal could rise unassisted and was nursing independently. Subsequent, repeat 128 
haematology at 60 hours post-partum showed a mild neutrophilia (11.17 109/L) and progressive 129 
rise in SAA (196 μg/mL) which decreased to 140 μg/mL by day 5. Mild hyperlactataemia 130 




The filly remained clinically normal with an average daily weight gain of 0.75 kg/day and was 133 
discharged on day 5 with one week of minocycline treatment (4 mg/kg orally q12h; 134 
Minocycline hydrochloride capsules)19 until lab work had normalized. The filly was PCR 135 
negative for A. phagocytophilum at the time of discharge. The mare required no further 136 
treatment at home, and both patients recovered uneventfully. 137 
Discussion 138 
This report documents the trans-placental transmission of A. phagocytophilum in a late-term 139 
pregnant mare, based on pre-colostral (immediate peri-partum) confirmation of infection in the 140 
foal. Variants of A. phagocytophilum are the causative agents of tick-borne fever in cattle, 141 
sheep, camelids and goats; canine, human and equine granulocytic anaplasmosis (EGA) 142 
(Woldehiwet, 2010). A. phagocytophilum is a tick-borne, gram negative, pleomorphic, 143 
intracellular bacteria, which forms macrocolonies known as morulae within infected 144 
granulocytes. Typical clinical signs observed in adult horses with EGA include pyrexia, 145 
anorexia, lower limb oedema, icterus, petechiation, reluctance to move, and ataxia, while 146 
laboratory findings may indicate thrombocytopenia, leukocytosis or leucopenia, anaemia, and 147 
hyperbilirubinaemia. Of these, historical pyrexia, mild leukopenia, hyperbilirubinaemia and 148 
significant thrombocytopenia were observed in the mare of the current report. Rhabdomyolysis 149 
(Hilton et al., 2008), cavitary effusion (Restifo et al., 2015), and premature parturition (Tinkler 150 
et al., 2012) are less commonly identified manifestations of EGA in various species. Neonatal 151 
anaplasmosis is infrequently observed and the route of infection remains uncertain (Dhand et 152 
al., 2007), but may include in utero infection, transmission at the time of delivery, or through 153 
milk (Horowitz et al., 1998). 154 
Transplacental transmission was the most likely route of infection in this foal, due to a lack of 155 
colostrum intake prior to the time of diagnostic (PCR) testing, immediately post-partum. The 156 
latter timing further precluded exposure to ticks and made disease transmission at the time of 157 
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delivery unlikely. Transplacental, intrauterine, or congenital infection with A. 158 
phagocytophilum (although a different strain to that which affects equines) has been previously 159 
reported in calves (Pusterla et al., 1997; Henniger et al., 2013), lambs (Reppert et al., 2013; 160 
Stuen et al., 2018), and humans (Horowitz et al., 1998; Dhand et al., 2007). For example, 161 
experimental intrauterine infection was induced in a cow, where the calf did not receive 162 
colostrum or milk from its dam and had no exposure to ticks (Pusterla et al., 1997). 163 
Additionally, naturally occurring in utero infection was identified in a calf based on the 164 
presence of morulae in the calf’s precolostral blood sample (Henniger et al., 2013), where the 165 
dam was thought to have been infected 2-3 weeks prior to delivery. In ewes, in utero infection 166 
has been documented after both acute infection during gestation (Reppert et al., 2013), and in 167 
chronically infected ewes that were exposed prior to the beginning of gestation (Stuen et al., 168 
2018). Of the chronically infected ewes, only those (n=3) that delivered positive lambs were 169 
identified as PCR positive at the time of parturition. Similarly, the mare in the current report 170 
showed anaplasma morulae on blood smear evaluation the day prior to parturition of a PCR 171 
positive foal.  172 
The pathophysiology of intra-uterine transmission of A. phagocytopilum may be associated 173 
with a vasculitis, resulting in placentitis, or be facilitated by the type of placentation, which 174 
varies between species. The mare has a nondeciduate, epitheliochorial, diffuse, 175 
microcotyledonary placenta. In general, the chorioallantoic placenta of domestic animals is 176 
classified by the number of distinct tissue layers that separate maternal and fetal blood 177 
(Stabenfeldt and Edqyist, 1993). Ruminants and camelids, like horses, have an epitheliochorial 178 
placentation, while dogs and cats show endotheliochorial, and primates haemochorial 179 
placentation. This would suggest that ruminants and horses are less likely to experience intra-180 
uterine transmission of pathogens compared to other species with less circulatory separation. 181 
Anaplasma-associated vasculitis is likely to occur due to one of two main mechanisms. A. 182 
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phagocytophilum may colonize endothelial cells with infection of microvascular endothelium, 183 
as demonstrated in vitro and in severe combined immune-deficiency mice (Munderloh et al., 184 
2004; Herron et al., 2005). Alternatively, production of myelosuppressive and proinflammatory 185 
cytokines by neutrophils can contribute to the development of vasculitis and oedema (Carlyon 186 
and Fikrig, 2003; Davies et al., 2011). Of these, INF-γ may be of particular importance given 187 
its potential role in pre-term birth due to placentitis (Lyle, 2014). However, in the current 188 
report, histopathology of the placenta did not identify evidence of placentitis. Nonetheless, the 189 
foal displayed abnormalities associated with placental insufficiency and tissue hypoxia, based 190 
on spurious hypercreatinemia, persistent hyperlactataemia, and slow behavioral development 191 
suggestive of neonatal encephalopathy; a manifestation of perinatal asphyxia syndrome. 192 
The foal’s post-partum inflammatory response and mild thrombocytopenia are comparable to 193 
clinical abnormalities identified in previous reports of neonatal anaplasmosis in other species 194 
(Horowitz et al., 1998; Henniger et al., 2013). For example, following late-term infection of a 195 
mother, her infant developed signs of fever, thrombocytopenia, and leukopenia at 9 days post-196 
partum without other clinical abnormalities, and completely recovered following 5 days of 197 
doxycycline therapy (Horowitz et al., 1998). Similarly, a calf developed fever, marked 198 
thrombocytopenia and intracellular morulae at 13 days of age, after experimental intrauterine 199 
infection (Pusterla et al., 1997). Following natural in utero infection, a calf of a second report 200 
showed an elevated rectal temperature from birth, with thrombocytopenia, leukopenia and 201 
anemia developing rapidly, and was euthanized at 4 days of age (Henniger et al., 2013). 202 
Similarly, an experimental study confirmed in utero infection in six lambs (delivered to 3 of 9 203 
ewes), of which 4 died within 2 days of birth (Stuen et al., 2018). The current literature suggests 204 
that the clinical manifestation of congenital anaplasma infection may range from mild to severe 205 
disease, supporting the decision to promptly treat the affected foal in the current report, while 206 
awaiting test results. The latter strategy may have prevented the development of more severe 207 
10 
 
thrombocytopenia and clinical illness. The observed elevation in SAA and mild neutrophilia 208 
are likely a direct response to inflammation caused by A. phagocytophilum. 209 
Alternative differential diagnosis for thrombocytopenia in a neonate include allo-imune 210 
disorders, which were ruled out in this case due to the lack of colostrum intake and the dam 211 
being a maiden mare. Decreased platelet production is also unlikely, as the platelet count 212 
increased during treatment, ruling out a hereditary defect in platelet production. There was also 213 
no evidence of increased platelet consumption such as disseminated intravascular coagulation, 214 
haemorrhage or thrombosis. Whilst thrombocytopenia secondary to sepsis cannot be fully 215 
excluded, anaplasmosis is considered to be the more likely cause in this case. 216 
Anaplasmosis is most often successfully treated with tetracyclines is all species, and more 217 
specifically oxytetracycline in horses (Dziegiel et al., 2013). However, use of this antimicrobial 218 
class may be undesirable in pregnant animals due to its teratogenic effects. Tetracyclines cross 219 
the placenta and form stable calcium complexes with bone-forming tissue, thus abnormalities 220 
will occur if administered during bone formation (Tötterman and Saxén, 1969). Evidence of 221 
bone abnormalities has not been directly demonstrated in horses, possibly due to the 222 
significantly longer gestation length compared to laboratory animals, resulting in fetal exposure 223 
to tetracycline for a smaller percentage of gestation in the horse. Late in gestation when tooth 224 
development is taking place, permanent discoloration and enamel hypoplasia may occur (Kline 225 
et al., 1964). Oxytetracycline administration in humans has the highest tetratogenic risk in the 226 
first trimester of pregnancy, with no increased risk (excluding dental discoloration) when 227 
exposed in the 9th month of gestation (Czeizel and Rockenbauer, 2000). However, alternative 228 
choices should still be considered, with rifampin and fluoroquinolones having some in vitro 229 
activity against A. phagocytophilum (Klein et al., 1997; Horowitz et al., 2001). 230 
Fluoroquinolones are known to be inhibitory to A. phagocytophilum, but are considered 231 
bacteriostatic and not bacteriocidal due to the high minimum inhibitory concentration (MIC) 232 
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required, with variable efficacy among different fluoroquinolones (Klein et al., 1997; Horowitz 233 
et al., 2001; Wormser et al., 2006). This variability, combined with known risks of 234 
fluoroquinolone-associated cartilage injury in neonates, makes them an unsatisfactory choice. 235 
The use of IV oxytetracycline in the foal was therefore justifiable, and is supported by the 236 
reported use of intravenous doxycycline in a human neonate (Horowitz et al., 1998). 237 
Enrofloxacin was administered to the mare to provide additional gram-negative bacterial 238 
coverage and tissue penetration following prolonged retention of fetal membranes. Considering 239 
existing concerns of renal injury associated with oxytetracycline to target anaplasma, 240 
polymyxin to counteract endotoxemia and flunixin for analgesic purposes, the use of an 241 
additional nephrotoxic medication (such as gentamicin) was avoided. Although milk 242 
concentrations of enrofloxacin or ciprofloxacin are not reported in mares, data from other 243 
species suggests that very low levels of enrofloxacin are found in milk (0.2% of administered 244 
dose) (Kaartinen et al., 1995), with higher concentrations of its active metabolite ciprofloxacin 245 
(Kaartinen et al., 1995; Aramayona et al., 1996; Haritova et al., 2003). However, studies in 246 
humans being treated with ciprofloxacin have identified no harm to the nursing child due to 247 
the low milk levels present and consumed (Kaplan and Koren, 2015). Therefore, despite the 248 
theoretical risk, enrofloxacin was considered safe to use short-term in lactating mares. 249 
In conclusion, this is the first documented case of transplacental anaplasmosis in a foal. The 250 
affected filly showed clinical signs of perinatal asphyxia syndrome despite normal parturition, 251 
which can indicate placental dysfunction. Congenital anaplasmosis should be considered in a 252 
foal delivered to a mare with EGA and antimicrobial therapy be guided accordingly. 253 
 254 
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Figure 1: Photograph demonstrating the presence of morulae in the mare’s neutrophils. 347 
 348 
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Table 1: Selected hematology and biochemistry values for the foal during hospitalization. 350 
Parameter Reference 
range† 
Time of sampling from birth (hours) 
0 h 12 h 24 h 48 h 60 h 72 h 100 h 
PCV‡ (%) 30-44 48 39 38 38 36 38 39 
Total solids (g/L) 41-66 52 53 48 49 50 52 50 
Lactate (mmol/L) 0.6-1.9 11.5 4.2 3.3 2.5 2.8 1.9 2 
Glucose (mmol/L) 5.6-12.9 2.6 10.3 8.4 8.8 9.4 7.8 11.1 
SAA‡ (µg/mL) 0-50 0  145  196  140 
WBC‡ (109/L) 6.2-12.4 9.7    11.2   
Neutrophils (109/L) 4.1-9.5 8.3    10.1   
Platelets (109/L) 129-409 87    102   
Fibrinogen (g/L) 1.0-4.0 1.0    2.0   
Creatinine (µmol/L) 106-380 292  71   71  
Globulin (g/L) 15-46 12       
Creatine Kinase (U/L) 165-761 2368       
Indirect bilirubin 
(µmol/L) 
17-51 89       
Anaplasma PCR‡  Positive      Negative 
†References ranges for foals at 1 day or 24-48 hours post-partum.(Orsini and Divers, 2014) 351 
‡PCV, packed cell volume; WBC, white blood cell count; SAA, serum amyloid A; PCR, 352 
polymerase chain reaction 353 
